Skip to content
HowShorted

OCULAR THERAPEUTIX, INC short interest in 2018

In 2018, OCULAR THERAPEUTIX, INC's disclosed short interest ran from 11.04% of shares outstanding on 12 Jan 2018 to 11.91% on 31 Dec 2018, a change of +0.87 percentage points. The year's high was 15.57% on 15 Feb 2018 and its low 9.50% on 15 Nov 2018, averaging 11.73% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.47 days on 30 Apr 2018. Full history: OCULAR THERAPEUTIX, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for OCULAR THERAPEUTIX, INC in 2018

2018 in figures

Start of year
11.04% (12 Jan 2018)
End of year
11.91% (31 Dec 2018)
Change
+0.87 pp
High
15.57% (15 Feb 2018)
Low
9.50% (15 Nov 2018)
Average
11.73%
Highest days to cover
26.47 (30 Apr 2018)
SEC filings marked
8

Every report in 2018

OCULAR THERAPEUTIX, INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201811.04%9.76
31 Jan 201812.68%4.37
15 Feb 201815.57%9.73
28 Feb 201815.18%14.75
15 Mar 201811.76%9.6410-K filed, results (8-K)
29 Mar 201812.09%8.34
13 Apr 201812.57%17.97
30 Apr 201811.73%26.47
15 May 201811.98%15.4510-Q filed, results (8-K)
31 May 201811.94%17.57
15 Jun 201812.26%10.09
29 Jun 201812.76%8.51
13 Jul 201812.03%10.12
31 Jul 201812.88%13.22
15 Aug 201811.72%14.6710-Q filed, results (8-K)
31 Aug 201811.16%11.02
14 Sep 201810.77%10.19
28 Sep 201810.00%8.22
15 Oct 20189.97%9.74
31 Oct 20189.73%9.62
15 Nov 20189.50%9.5210-Q filed, results (8-K)
30 Nov 20189.56%9.18
14 Dec 201810.84%4.54
31 Dec 201811.91%6.46

See also: OCULAR THERAPEUTIX, INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.